WALTHAM, Mass.--(BUSINESS WIRE)--
Inc. (Nasdaq: IMGN), a biotechnology company that develops targeted
anticancer products using its antibody expertise and Targeted Antibody
Payload (TAP) technology, today announced that the Company will host a
conference call at 8:00 a.m. ET on Friday, August 3, 2012, to discuss
ImmunoGen's financial results for the three-month period and fiscal year
ended June 30, 2012. Management also will provide an update on the
Company and guidance for ImmunoGen's fiscal year ending June 30, 2013.
To access the live call by phone, dial 913-312-1510. Passcode: 6959547.
The call also may be accessed through the Investor Information section
of the Company's website, http://www.immunogen.com.
Following the live webcast, a replay of the call will be available at
the same location through August 17, 2012.
About ImmunoGen, Inc.
ImmunoGen, Inc. develops targeted anticancer therapeutics using the
Company's expertise in tumor biology, monoclonal antibodies, potent
cancer-cell killing agents and engineered linkers. The Company's TAP
technology uses monoclonal antibodies to deliver one of ImmunoGen's
proprietary cancer-killing agents specifically to tumor cells. There are
now ten TAP compounds in clinical development, of which three are wholly
owned by the Company. ImmunoGen's collaborative partners include Amgen,
Bayer HealthCare, Biotest, Lilly, Novartis, Roche, and Sanofi. The most
advanced compound using ImmunoGen's TAP technology, trastuzumab
emtansine, is in Phase III testing through the Company's collaboration
with Genentech, a member of the Roche Group. More information about
ImmunoGen can be found at www.immunogen.com.
Carol Hausner, 781-895-0600
Director, Investor Relations and Corporate Communications
The Yates Network
Barbara Yates, 781-258-6153
Source: ImmunoGen, Inc.
News Provided by Acquire Media